Merck & Co., Inc. (MRK) to Distribute Quarterly Dividend of $0.85 on October 7th

Posted by Brian Himes on Jul 31st, 2026

Merck & Co., Inc. (NYSE:MRK – Get Free Report) declared a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of 0.85 per share on Wednesday, October 7th. This represents a c) dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Tuesday, September 15th.

Merck & Co., Inc. has raised its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. Merck & Co., Inc. has a payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Merck & Co., Inc. to earn $9.72 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 35.0%.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $129.95 on Friday. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market capitalization of $320.96 billion, a P/E ratio of 36.61, a P/E/G ratio of 5.17 and a beta of 0.19. The stock has a 50 day moving average price of $123.02 and a 200 day moving average price of $118.37.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the business earned $2.22 EPS. Merck & Co., Inc.’s revenue was up 4.9% compared to the same quarter last year. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.